CDKN2A and neoplasm: In vivo experiments, using the p16-3MR model of senescence, showed that leukemic blast derived superoxide induces p16INK4A driven senescence in BMSCs (CD45-, CD105+, CD140a+, CD31– and ter119–) and that deletion of these senescent BMSCs slows tumor progression and prolongs animal survival (49).